推荐产品
等级
pharmaceutical primary standard
API类
bezafibrate
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O
InChI
1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
InChI key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
基因信息
human ... PPARA(5465) , PPARD(5467) , PPARG(5468)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Bezafibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
过氧化物酶体增殖物激活受体（PPAR）是类固醇核受体超家族成员之一。苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
预防措施声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
C G Ericsson
European heart journal, 19 Suppl H, H37-H41 (1998-08-26)
Bezafibrate is a latest generation fibrate derivative that substantially reduces total plasma cholesterol and triglyceride concentrations and increases high density lipoprotein (HDL) cholesterol. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a double-blind, placebo-controlled trial over 5 years to assess
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Alexander Tenenbaum et al.
Cardiovascular diabetology, 4, 14-14 (2005-09-20)
There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results
U de Faire et al.
European heart journal, 17 Suppl F, 37-42 (1996-12-01)
Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol.
Alexander Tenenbaum et al.
Cardiovascular diabetology, 11, 140-140 (2012-11-16)
All fibrates are peroxisome proliferators-activated receptors (PPARs)-alpha agonists with ability to decrease triglyceride and increase high density lipoprotein- cholesterol (HDL-C). However, bezafibrate has a unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta)
R Manfredi et al.
The Journal of infection, 42(3), 181-188 (2001-09-08)
To assess the correlation between antiretroviral treatment and dyslipidaemia in HIV-infected patients, and the role of bezafibrate as a lipid-lowering agent. We retrospectively compared serum lipid levels of five groups of 40 patients, each of them treated with either saquinavir
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门